Endo, Novartis enter deal for marketing rights for Voltaren gel

WASHINGTON Endo Pharmaceuticals and Novartis have entered a licensing agreement in which Endo is trying to gain the U.S. marketing rights for Voltaren gel.

Voltaren gel (diclofenac sodium) received its approval from the Food and Drug Administration in 2007, and has been given market exclusivity in the United States until October 2010, which Endo is trying to purchase from Novartis.

The deal made by Novartis and Endo promises an $85 million upfront cash payment to Novartis. If the annual sales of Voltaren gel exceed $300 million, Endo may also give Novartis a $25 million milestone payment. Novartis, according to published reports, is also expected to receive royalties.